Urea
Names
[ CAS No. ]:
57-13-6
[ Name ]:
Urea
[Synonym ]:
Carbonyl diamide
diaminomethanal
Urea
UREUM
Carbamide
EINECS 200-315-5
MFCD00008022
carbonyl diamine
Urea (8CI,9CI)
Biological Activity
[Description]:
[Related Catalog]:
[Target]
Human Endogenous Metabolite
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.335
[ Boiling Point ]:
332.48°C
[ Melting Point ]:
131-135 ºC
[ Molecular Formula ]:
CH4N2O
[ Molecular Weight ]:
60.055
[ Flash Point ]:
53.7±22.6 °C
[ Exact Mass ]:
60.032364
[ PSA ]:
69.11000
[ LogP ]:
-1.43
[ Vapour Pressure ]:
<0.1 hPa (20 °C)
[ Index of Refraction ]:
n20/D 1.40
[ Storage condition ]:
2-8°C
[ Stability ]:
Substances to be avoided include strong oxidizing agents. Protect from moisture.
[ Water Solubility ]:
1080 g/L (20 ºC)
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- YR6250000
- CHEMICAL NAME :
- Urea
- CAS REGISTRY NUMBER :
- 57-13-6
- LAST UPDATED :
- 199710
- DATA ITEMS CITED :
- 43
- MOLECULAR FORMULA :
- C-H4-N2-O
- MOLECULAR WEIGHT :
- 60.07
- WISWESSER LINE NOTATION :
- ZVZ
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- Standard Draize test
- ROUTE OF EXPOSURE :
- Administration onto the skin
- SPECIES OBSERVED :
- Human
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 8471 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >5 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 8200 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 5300 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intratracheal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 567 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea Blood - methemoglobinemia-carboxyhemoglobin
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 11 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 6608 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - coma
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 9200 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 4600 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay) Behavioral - antipsychotic
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 3 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 3 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 3 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 4800 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Bird - pigeon
- DOSE/DURATION :
- 14800 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Amphibian - frog
- DOSE/DURATION :
- 600 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - domestic
- DOSE/DURATION :
- 511 mg/kg
- TOXIC EFFECTS :
- Behavioral - tetany Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - changes in structure or function of salivary glands
- TYPE OF TEST :
- TCLo - Lowest published toxic concentration
- ROUTE OF EXPOSURE :
- Inhalation
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 288 mg/m3/17W-I
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - other changes in urine composition Blood - other changes Nutritional and Gross Metabolic - changes in chlorine
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Administration onto the skin
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 3024 mg/kg/4W-C
- TOXIC EFFECTS :
- Liver - changes in liver weight Endocrine - changes in thymus weight Related to Chronic Data - changes in testicular weight
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Administration onto the skin
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 37800 mg/kg/25W-C
- TOXIC EFFECTS :
- Brain and Coverings - changes in brain weight Related to Chronic Data - changes in prostate weight
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 821 gm/kg/1Y-C
- TOXIC EFFECTS :
- Tumorigenic - neoplastic by RTECS criteria Blood - tumors Blood - lymphoma, including Hodgkin's disease
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 394 gm/kg/1Y-C
- TOXIC EFFECTS :
- Tumorigenic - Carcinogenic by RTECS criteria Blood - tumors Blood - lymphoma, including Hodgkin's disease
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraplacental
- DOSE :
- 1400 mg/kg
- SEX/DURATION :
- female 16 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - abortion
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraplacental
- DOSE :
- 1600 mg/kg
- SEX/DURATION :
- female 16 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - abortion
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraplacental
- DOSE :
- 1600 mg/kg
- SEX/DURATION :
- female 16 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - abortion
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intrauterine
- DOSE :
- 6 gm/kg
- SEX/DURATION :
- female 18 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - abortion
- TYPE OF TEST :
- Cytogenetic analysis
MUTATION DATA
- TYPE OF TEST :
- Cytogenetic analysis
- TEST SYSTEM :
- Rodent - hamster Lung
- DOSE/DURATION :
- 13 gm/L
- REFERENCE :
- GMCRDC Gann Monograph on Cancer Research. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) No. 11- 1971- Volume(issue)/page/year: 27,95,1981 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80231 No. of Facilities: 22367 (estimated) No. of Industries: 156 No. of Occupations: 119 No. of Employees: 284911 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X7915 No. of Facilities: 9 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 63 (estimated) No. of Female Employees: 9 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80231 No. of Facilities: 31269 (estimated) No. of Industries: 204 No. of Occupations: 164 No. of Employees: 783504 (estimated) No. of Female Employees: 326824 (estimated)
Safety Information
[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
[ Hazard Codes ]:
Xn,Xi
[ Risk Phrases ]:
36/37/38-40
[ Safety Phrases ]:
S26-S36-S24/25
[ RIDADR ]:
NONH for all modes of transport
[ WGK Germany ]:
1
[ RTECS ]:
YR6250000
[ HS Code ]:
3102100001
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 3102100001
Articles
Vet. Parasitol. 207(3-4) , 266-75, (2015)
The mechanisms involved in anthelmintic resistance (AR) are complex but a greater understanding of AR management is essential for effective and sustainable control of parasitic helminth worms in lives...
Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking.Autophagy 10(7) , 1241-55, (2014)
Glioblastoma is one of the most aggressive human cancers with poor prognosis, and therefore a critical need exists for novel therapeutic strategies for management of glioblastoma patients. Itraconazol...
Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.Eur. J. Pharm. Biopharm. 88(2) , 406-14, (2014)
Polycaprolactone (PCL) matrices were simultaneously loaded with the antiviral agents, tenofovir (TFV) and nevirapine (NVP), in combination to provide synergistic activity in the prevention of HIV tran...